This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.
This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterise the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments.
Funding & Duration
Direct costs are limited to US $275,000 (approx AUD $380,000) over an R21 two-year period, with no more than US $200,000 (approx AUD $276,000) in direct costs allowed in any single year.
The maximum project period is 2 years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
- Applications must be submitted for internal review by 30 September 2016
- The University’s Grant Application Cover Sheet must accompany your application
- Email: email@example.com